Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

IMMX

Immix Biopharma Inc

Apr 24 • 04:00PM ET

2.13

Dollar change -0.17
Percentage change -7.39	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF IWC DFUS DCOR

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.90	Insider Own	47.54%	Shs Outstand	19.92M	Perf Week	-14.80%
Market Cap	56.23M	Forward P/E	-	EPS next Y	-1.01	Insider Trans	0.45%	Shs Float	13.85M	Perf Month	-33.23%
Income	-15.43M	PEG	-	EPS next Q	-	Inst Own	8.47%	Short Float	2.81%	Perf Quarter	-54.49%
Sales	0.00M	P/S	-	EPS this Y	-24.00%	Inst Trans	19.81%	Short Ratio	1.41	Perf Half Y	-38.26%
Book/sh	0.82	P/B	2.59	EPS next Y	-8.60%	ROA	-88.57%	Short Interest	0.39M	Perf Year	18.99%
Cash/sh	0.66	P/C	3.21	EPS next 5Y	-	ROE	-104.35%	52W Range	1.40 - 7.75	Perf YTD	-69.22%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-63.30%	ROI	-94.03%	52W High	-72.52%	Beta	0.19
Dividend TTM	-	Quick Ratio	5.32	Sales past 5Y	0.00%	Gross Margin	-	52W Low	52.14%	ATR (14)	0.28
Dividend Ex-Date	-	Current Ratio	5.32	EPS Y/Y TTM	-48.76%	Oper. Margin	0.00%	RSI (14)	31.17	Volatility	11.94% 10.78%
Employees	17	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	14.00
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	11.04%	Payout	-	Rel Volume	0.22	Prev Close	2.30
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	276.29K	Price	2.13
SMA20	-21.79%	SMA50	-27.79%	SMA200	-39.49%	Trades		Volume	59,773	Change	-7.39%

Apr-18-24 09:37AM	Nexcella, an Immix Biopharma Subsidiary, on Track to Dose NXC-201 Patients in United States (GlobeNewswire) -11.60%
09:32AM	Immix Biopharma on Track to Dose NXC-201 Patients in United States (GlobeNewswire)
Apr-15-24 09:36AM	Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) (GlobeNewswire)
Apr-02-24 07:53AM	IMMX Stock Earnings: Immix Biopharma Misses EPS for Q4 2023 (InvestorPlace)
Mar-20-24 09:46AM	Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial (GlobeNewswire)
09:35AM	Loading…
Mar-05-24 09:35AM	Immix Biopharma Announces Be Proactive in AL AL Amyloidosis Awareness Initiative (GlobeNewswire) -8.06%
Feb-21-24 09:31AM	Immix Biopharma 12 Month Review Progress Update (GlobeNewswire)
Feb-08-24 04:45PM	Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock (GlobeNewswire) +6.60%
Feb-07-24 09:37AM	Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis (GlobeNewswire) +7.07%
Feb-05-24 10:30PM	Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock (GlobeNewswire) -19.89%
03:20PM	Immix Biopharma Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Jan-24-24 08:35AM	Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products (GlobeNewswire)
Jan-04-24 09:34AM	Immix Biopharma Announces Dr. Vaishali Sanchorawala, AL Amyloidosis Thought Leader, Director of the Amyloidosis Center at Boston University and Boston Medical Center, Joins Scientific Advisory Board (GlobeNewswire)
Dec-18-23 09:39AM	Immix Biopharma Announces Dr. Marko Radic, Autoimmune CAR-T Pioneer and Associate Professor at the University of Tennessee Health Science Center, Joins Scientific Advisory Board (GlobeNewswire) -8.94%
Dec-11-23 09:36AM	Immix Biopharma Announces 100% Overall Response Rate (n=10); 23.7 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2023 (GlobeNewswire)
09:46AM	Loading…
Nov-30-23 09:46AM	Immix Biopharma to Present at the 2023 JMP Securities Hematology and Oncology Summit (GlobeNewswire)
Nov-28-23 08:50AM	What Makes Immix Biopharma, Inc. (IMMX) a Good Fit for 'Trend Investing' (Zacks) +5.39%
Nov-22-23 11:10AM	Immix (IMMX) CAR-T Therapy IND Cleared by FDA, Stock Down (Zacks) +5.01%
09:19AM	Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL Amyloidosis (GlobeNewswire)
Nov-21-23 09:46AM	Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing (GlobeNewswire)
Nov-06-23 09:18AM	Nexcella Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 9 Relapsed/Refractory AL Amyloidosis Patients (GlobeNewswire) +20.73%
09:12AM	Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 9 Relapsed/Refractory AL Amyloidosis Patients (GlobeNewswire)
08:40AM	Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 63 Relapsed/Refractory Multiple Myeloma Patients (GlobeNewswire)
Oct-31-23 09:55AM	Here's Why Immix Biopharma, Inc. (IMMX) Is a Great 'Buy the Bottom' Stock Now (Zacks) +9.37%
Oct-26-23 08:58AM	Immix Biopharma Subsidiary Nexcella Announces Dr. Michaela Liedtke, Stanford Medicine Cancer Center Hematology Program Lead and Co-Director Stanford Amyloid Center, Joins Scientific Advisory Board (GlobeNewswire)
Oct-16-23 09:05AM	Immix Biopharma Completes 3rd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site (GlobeNewswire)
Oct-03-23 09:14AM	Immix Biopharma Announces Complete Response in 9th Relapsed/Refractory AL Amyloidosis Patient in NXC-201 Clinical Trial at IMS 20th Annual Meeting (GlobeNewswire) +5.31%
Oct-02-23 08:06AM	Immix Biopharma Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma (GlobeNewswire) +26.61%
Sep-22-23 12:04PM	Immix (IMMX) Up on Orphan Drug Tag for AL Amyloidosis Therapy (Zacks)
Sep-21-23 08:55AM	U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Amyloid Light Chain (AL) Amyloidosis (GlobeNewswire) +15.38%
09:10AM	Loading…
Sep-19-23 09:10AM	Immix Biopharma Subsidiary Nexcella Completes 2nd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site (GlobeNewswire) +24.15%
Sep-15-23 01:18PM	Director Helen Adams Buys 13,000 Shares of Immix Biopharma Inc (IMMX) (GuruFocus.com) +5.12%
Sep-07-23 10:38AM	The 3 Best Speculative Stocks to Buy Now: September 2023 (InvestorPlace)
08:41AM	Nexcella, Immix Biopharma Subsidiary, to Present at the Bank of America 2023 Healthcare Trailblazers Private Company Conference (GlobeNewswire)
Sep-01-23 08:39AM	Immix Biopharma Announces Dr. Suzanne Lentzsch, Director of the Multiple Myeloma and Amyloidosis Program at the College of Physicians and Surgeons of Columbia University and at New York Presbyterian Hospital in New York, Joins Scientific Advisory Board (GlobeNewswire) +12.81%
Aug-23-23 08:37AM	U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Multiple Myeloma (GlobeNewswire) +11.11%
Aug-18-23 09:20AM	Immix Biopharma Announces Dr. Heather Landau, Memorial Sloan Kettering Cancer Center Amyloidosis Program Director, Joins Nexcella Scientific Advisory Board (GlobeNewswire) +6.13%
Aug-16-23 09:05AM	Immix Biopharma Announces Additional NXC-201 AL Amyloidosis Clinical Data Accepted for Oral Presentation at the 20th International Myeloma Society Annual Meeting (September 27-30, Athens Greece) (GlobeNewswire)
Jul-25-23 08:42AM	Immix Biopharma Subsidiary Nexcella Announces NXC-201 Multiple Myeloma Clinical Data Abstract Accepted for Presentation at the 20th International Myeloma Society Annual Meeting (GlobeNewswire)
Jul-17-23 09:37AM	Immix Biopharma Reports 2nd Positive Interim Clinical Trial Data Readout in Relapsed/Refractory Metastatic Colorectal Cancer in Ongoing Phase 1b/2a IMX-110 IMMINENT-01 Clinical Trial (GlobeNewswire) -6.11%
Jul-10-23 09:47AM	Immix Biopharma Subsidiary Nexcella Completes Initial NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site (GlobeNewswire)
Jun-26-23 09:49AM	Immix Biopharma Subsidiary Nexcella Completes Pre-IND Meeting with FDA on NXC-201 US Clinical Trial (GlobeNewswire) -6.90%
Jun-22-23 09:53AM	Immix Biopharma Subsidiary Nexcella Appoints Edward J. Borkowski, former Chief Financial Officer of Mylan N.V, to Board of Directors (GlobeNewswire)
Jun-20-23 09:45AM	Immix Biopharma Subsidiary Nexcella Appoints Jeffrey H. Cooper, former Chief Financial Officer of BioMarin, to Board of Directors (GlobeNewswire) +8.11%
Jun-16-23 09:43AM	Immix Biopharma Subsidiary Nexcella Appoints Mary Sue Coleman, former Johnson & Johnson Independent Director, to Board of Directors (GlobeNewswire) -5.93%
Jun-14-23 07:30AM	Immix Biopharma Completes $5 Million At-The-Market Equity Offering Program (GlobeNewswire)
Jun-12-23 09:49AM	Immix Biopharma Subsidiary Nexcella Appoints Henry McKinnell, Jr., former Chairman & CEO of Pfizer Inc., to Board of Directors (GlobeNewswire)
May-26-23 09:53AM	Immix Biopharma Subsidiary Nexcella Announces Commencement of NXC-201 Engineering Batches at its U.S. CAR-T Manufacturing Site (GlobeNewswire) +9.38%
May-22-23 01:48PM	Immix Biopharma's Subsidiary Says Investigational CAR T Therapy Shows 100% Response Rate In Amyloidosis (Benzinga) +6.71%
08:31AM	We Think Immix Biopharma (NASDAQ:IMMX) Needs To Drive Business Growth Carefully (Simply Wall St.)
May-21-23 04:05PM	Nexcella Announces Positive NXC-201 Clinical Results at ASGCT: 100% Overall Response Rate in DARZALEX-Relapsed/Refractory AL Amyloidosis with Zero ICANs in Ongoing NEXICART-1 Phase 1b/2a Clinical Trial (GlobeNewswire)
04:00PM	Immix Biopharma Announces Positive NXC-201 Clinical Results at ASGCT: 100% Overall Response Rate in DARZALEX-Relapsed/Refractory AL Amyloidosis with Zero ICANs in Ongoing NEXICART-1 Phase 1b/2a Clinical Trial (GlobeNewswire)
May-04-23 12:30PM	Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 26th Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT) (GlobeNewswire)
May-03-23 04:42PM	What's Going On With Immix Biopharma Stock Today (Benzinga)
08:00AM	Immix Biopharma Announces Early Positive IMX-110 Interim Clinical Trial Data Demonstrating 100% Tumor Shrinkage in Advanced Metastatic Colorectal Cancer at the Lowest Dose of IMX-110 + BeiGene / Novartis Anti-PD-1 Antibody Tislelizumab (GlobeNewswire)
Apr-26-23 05:30PM	Nexcella, an Immix Biopharma subsidiary, Announces Positive 58-Patient NXC-201 Clinical Data: 100% Overall Response Rate in Light Chain (AL) Amyloidosis; 92% Overall Response Rate in Multiple Myeloma at the EBMT 49th Annual Meeting in Paris (GlobeNewswire)
Apr-04-23 08:00AM	Nexcella, an Immix Biopharma subsidiary, announces poster presentation at the European Society for Blood and Marrow Transplantation 49th Annual Meeting (GlobeNewswire) -7.45%
Mar-31-23 08:00AM	Nexcella, an Immix Biopharma Subsidiary, Announces 2023 Haematologica Editorial Highlighting NXC-201 Efficacy In The Context of U.S. Food And Drug Administration Approved BCMA CAR T Cells (GlobeNewswire) +5.81%
Mar-23-23 08:00AM	Nexcella, an Immix Biopharma Subsidiary, Announces New Positive NXC-201 Clinical Data Demonstrating 100% Complete Responses in AL Amyloidosis Patients + Additional Positive Multiple Myeloma Safety Data Demonstrating NXC-201 Outpatient CAR-T Treatment Potential (GlobeNewswire) -7.94%
Mar-10-23 07:45PM	Immix Biopharma Confirms No Exposure to Silicon Valley Bank or Silvergate Bank (GlobeNewswire) -7.69%
Mar-06-23 08:00AM	ImmixBio to Discuss Recent Positive NXC-201 Clinical Data in AL Amyloidosis and Multiple Myeloma at the 35th Annual Roth Conference on March 14 (GlobeNewswire)
Feb-27-23 08:45AM	Nexcella Announces 50 Patients Already Treated with CAR-T NXC-201; Estimates 100-Patient Total Enrollment for U.S. Food and Drug Administration Approval BLA Submission (GlobeNewswire)
Feb-15-23 08:30AM	Immix Biopharma Subsidiary Nexcella Enters into U.S. GMP Manufacturing Agreement to Expand Ongoing NXC-201 Phase 1b/2 Clinical Trial to the U.S. (GlobeNewswire)
Feb-09-23 08:00AM	Immix Biopharma Subsidiary Nexcella, Inc. Presents 42-Patient Interim Data, with 90% Overall Response Rate in Relapsed or Refractory Multiple Myeloma at NXC-201 Therapeutic Dose from its Phase 1 Expansion Trial at the 5th European CAR T-cell Meeting (GlobeNewswire) -16.59%
Feb-07-23 08:00AM	Immix Biopharma Announces Dosing of First 2 Patients in its IMX-110 + BeiGene/Novartis anti-PD-1 Tislelizumab Phase 1b/2a Combination Clinical Trial in Patients with Advanced Cancer (GlobeNewswire) -8.01%
Jan-13-23 08:00AM	Immix Biopharma Doses Additional Patients in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial (GlobeNewswire)
Jan-06-23 08:00AM	Immix Biopharma Subsidiary Nexcella, Inc. Announces Additional Positive NXC-201 Clinical Data Demonstrating 100% Complete Responses in Relapsed/Refractory AL Amyloidosis Patients, Duration of Response Not Yet Reached (GlobeNewswire) -8.24%
Dec-28-22 08:00AM	Nexcella, Inc., a subsidiary of Immix Biopharma, announces poster presentation at the European Society for Blood and Marrow Transplantation and European Hematology Association 5th Annual European CAR T-cell Meeting (GlobeNewswire) +8.50%
Dec-20-22 08:00AM	Immix Biopharma Announces 16th Patient Dosing in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial (GlobeNewswire) -5.08%
Dec-19-22 08:00AM	ImmixBio Ships Tislelizumab for Patient Dosing in its Combination Clinical Trial with IMX-110 in Advanced Solid Tumors (GlobeNewswire)
Dec-14-22 12:43PM	Why Immix Biopharma Shares Are Surging Today? (Benzinga) +23.29%
08:00AM	Immix Biopharma in-licenses NXC-201, BCMA-targeted Next-Generation CAR-T Therapy Demonstrating High Complete Response Rate in Heavily Pre-Treated Multiple Myeloma (71% Complete Responses) and AL Amyloidosis (100% Complete Responses) (GlobeNewswire)
Dec-13-22 08:00AM	Immix Biopharma Announces Patient Dosing in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial (GlobeNewswire)
05:06AM	We're Hopeful That Immix Biopharma (NASDAQ:IMMX) Will Use Its Cash Wisely (Simply Wall St.)
Dec-12-22 08:00AM	ImmixBio Releases and Ships Scaled-Up GMP Batches of IMX-110 for Clinical Trial Patient Dosing (GlobeNewswire) +7.91%
Nov-11-22 08:00AM	Immix Biopharma Receives Institutional Review Board Approval to Enroll Pediatric Patients in Upcoming IMX-110 Clinical Trial, Key Requirement for U.S. Food and Drug Administration Approval of Rare Pediatric Disease Priority Review Voucher (GlobeNewswire) +16.67%
Oct-25-22 08:00AM	Immix Biopharma to Present Milestones Achieved to Enable Kick-Off of 2 IMX-110 Clinical Trials at the 2022 ThinkEquity Conference on October 26 (GlobeNewswire)
Oct-18-22 08:00AM	ImmixBio Approves 4 Additional Clinical Trial Sites for IMX-110 Clinical Trials, Complementing Existing Soft Tissue Sarcoma Lead Site (GlobeNewswire)
Sep-07-22 12:05PM	ImmixBio Completes GMP Manufacturing of Scaled-Up Batch of IMX-110 for Clinical Trials (GlobeNewswire)
Aug-23-22 06:36AM	Insiders who bought in the last 12 months lose an additional US$175k as Immix Biopharma, Inc. (NASDAQ:IMMX) drops to US$28m (Simply Wall St.)
Aug-01-22 10:10AM	10 Best Penny Stocks to Buy and Hold According to Reddit (Insider Monkey)
May-21-22 08:26AM	We Think Immix Biopharma (NASDAQ:IMMX) Can Afford To Drive Business Growth (Simply Wall St.)
May-20-22 10:19AM	ImmixBio's Lead Candidate Shows Improved Survival Over FDA-Approved Soft Tissue Cancer Drug (Benzinga) +30.06%
08:47AM	ImmixBio IMX-110 Demonstrated Improved Survival Over U.S. Food and Drug Administration Approved Drug Trabectedin (sold as YONDELIS ® by Janssen, a Johnson & Johnson Company) in Connective Tissue Cancer Soft Tissue Sarcoma Mice Study (GlobeNewswire)
May-09-22 08:00AM	Immix Biopharma Announces Share Repurchase Program (GlobeNewswire)
Apr-05-22 09:30AM	ImmixBio Management Discusses Key Milestones, Drug Development Timelines and the IMMX Advantage at IMMX Milestone Day Event Held on April 5, 2022 (GlobeNewswire) -22.01%
Mar-16-22 10:13AM	Multiple insiders bought Immix Biopharma, Inc. (NASDAQ:IMMX) stock earlier this year, a positive sign for shareholders (Simply Wall St.) +19.12%
Mar-07-22 08:00AM	Immix Biopharma, Inc. Announces IMMX Milestone Day to be Held on April 5, 2022 (GlobeNewswire) -10.90%
Feb-22-22 08:00AM	ImmixBio Initiates GMP Manufacturing of IMX-120, a Biologic for Inflammatory Bowel Disease (GlobeNewswire) -9.50%
Feb-01-22 11:36AM	5 Short-Squeeze Candidates to Watch Today: IMMX, ALTM, GLTB, CRTX and TSRI (InvestorPlace) +13.55%
09:30AM	ImmixBio Management Answers Top-Voted Investor Questions at IMMX Investors Day February 1, 2022 (GlobeNewswire)
Jan-31-22 08:00AM	ImmixBio Initiates IMX-110 GMP Manufacturing Scale-Up, Potentially Accelerating Clinical Trial Data (GlobeNewswire)
Jan-25-22 12:17PM	Immix Biopharma's IMX-110 / Anti-PD-1 Combo Therapy Shows Extended Median Survival In Animal Studies (Benzinga)
10:15AM	IMX-110 + anti-PD-1 Combination Produced Extended Median Survival in Genetic Pancreatic Cancer Mouse Model, Bolstering Planned 2022 IMX-110 Combination Clinical Trial Rationale (GlobeNewswire)
Jan-19-22 08:00AM	ImmixBio Announces Positive IMX-110 Phase 1b/2a Interim Clinical Trial Safety Data Demonstrating 100% Completion of Planned Treatment Cycles (GlobeNewswire)
Jan-12-22 08:43AM	Immix's Lead Program Shows 50% Response Rate In Resistant Cancer In Animal Study (Benzinga) +18.42%
08:00AM	ImmixBio IMX-110 Produced 50% Positive Response Rate in First-Line-Therapy-Resistant Cancer, Surpassing the Standard of Care in Mice Study (GlobeNewswire)
Jan-06-22 09:00AM	Immix Biopharma Announces IMMX Investors Day to be Held on February 1, 2022 + Q&A Platform for All Shareholders (GlobeNewswire) -18.67%
Jan-03-22 10:46AM	IMMX Stock Alert: The Massive FDA Win That Has Immix Biopharma Blasting Higher Today (InvestorPlace) +62.36%
09:15AM	Immix Shares Rally On FDA Rare Pediatric Disease Tag For Cancer Program In Children (Benzinga)

Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company was founded by Ilya Rachman, Sean Senn, and Vladimir Torchilin in 2012 and is headquartered in Los Angeles, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hsu Jason	Director	Dec 11 '23	Buy	4.67	31,000	144,894	813,000	Dec 12 06:25 PM
Hsu Jason	Director	Dec 08 '23	Buy	4.88	25,000	122,025	782,000	Dec 12 06:25 PM
Hsu Jason	Director	Sep 15 '23	Buy	2.49	7,000	17,396	757,000	Sep 18 07:03 PM
Hsu Jason	Director	Sep 14 '23	Buy	2.58	10,000	25,772	750,000	Sep 18 07:03 PM
Ng Carey	Director	Sep 14 '23	Buy	2.58	10,000	25,760	10,000	Sep 15 06:27 PM
Hsu Jason	Director	Sep 12 '23	Buy	2.83	30,000	84,864	740,000	Sep 18 07:03 PM
Adams Helen C.	Director	Sep 12 '23	Buy	2.96	13,000	38,492	13,000	Sep 14 05:20 PM
Hsu Jason	Director	Sep 11 '23	Buy	2.89	25,000	72,280	710,000	Sep 18 07:03 PM
Hsu Jason	Director	Sep 08 '23	Buy	2.53	10,000	25,317	685,000	Sep 12 04:58 PM
BUCHAN MELISSA JANE	Director	Sep 07 '23	Buy	2.46	20,000	49,226	20,000	Sep 11 05:18 PM
Marquet Magda	Director	Sep 06 '23	Buy	2.47	9,000	22,213	20,000	Sep 08 05:46 PM
Marquet Magda	Director	Sep 05 '23	Buy	2.47	10,000	24,722	11,000	Sep 06 04:33 PM
Marquet Magda	Director	Aug 31 '23	Buy	2.01	1,000	2,010	1,000	Sep 05 06:43 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IMMX

Immix Biopharma Inc

Upgrade your FINVIZ experience